Pharmacodynamic of antithrombotic drugSulfinpyrazone: Relationship between dose, kinetics, plasma concentrations and biological effects
References (20)
- et al.
A study of the inverse relationship between pKa and rate of renal excretion of phenylbutazone analogs in man and dogs
Amer. J. Med.
(1960) - et al.
The prolonged effect of sulfinpyrazone on collagen induced platelet aggregation in vivo
Thromb. Res.
(1978) - et al.
Thromboxane B2 and 6-keto-prostaglandin F1 synthesis during infusion of collagen and arachidonic acid in rabbits: inhibition by aspirin and sulfinpyrazone
Thromb. Res.
(1980) Mechanisms of action of sulphinpyrazone
Thromb. Res.
(1983)- et al.
A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue G25671
J. Pharmacol. Exp. Ther.
(1957) - et al.
Observations on G-25671, a phenylbutazone analogue (4-phenyl-thioethyl)-1,2-diphenyl 3,5,pyrazolidinedione
- et al.
Evaluation of uricosuric agents in chronic gout
Ann. Rheum. Dis.
(1957) - et al.
Metabolism for sulfinpyrazone (Anturane) and other thioanalogues of phenylbutazone in man
J. Pharmacol. Exp. Ther.
(1961) - et al.
Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man
Europ. J. Clin. Pharmacol.
(1975) - et al.
Excretion of sulfinpyrazone in the rat
Can. J. Physiol. Pharmacol.
(1972)
There are more references available in the full text version of this article.
Cited by (5)
PROSPECTS OF ANTI-INFLAMMATORY AND URATE-LOWERING THERAPY OF GOUT: A VECTOR FROM THE PAST TO THE FUTURE
2022, Nauchno-Prakticheskaya RevmatologiyaGout: Basic science and clinical practice
2013, Gout: Basic Science and Clinical Practice
Copyright © 1983 Published by Elsevier Ireland Ltd.